Screener
Royalty Pharma RPRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's EBITDA margin?
- Royalty Pharma (RPRX) reported EBITDA margin of 57.1% in Q4 2024.
- How has Royalty Pharma's EBITDA margin changed year-over-year?
- Royalty Pharma's EBITDA margin decreased by 9.9% year-over-year, from 63.4% to 57.1%.
- What is the long-term trend for Royalty Pharma's EBITDA margin?
- Over 3 years (2020 to 2024), Royalty Pharma's EBITDA margin has grown at a -9.2% compound annual growth rate (CAGR), from 76.3% to 57.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Royalty Pharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude